Deepak Bhamidipati, Assistant Director of Drug Development at Sarah Cannon Research Institute, shared on LinkedIn:
“Big week for RAS-targeted therapies at ENA 2026.
A few key takeaways:
Daraxonrasib + GnP in 1L metastatic PDAC: Really compelling data, with a median PFS of 12.8 months and an ORR of 60.7%. Curious to see how daraxonrasib monotherapy compares with the GnP combination in the ongoing RASolute-303 trial. Is there true synergy?
ALTA3263: A pan-mutant KRAS inhibitor (ON/OFF) demonstrated a 31% ORR in combination with cetuximab in CRC. Some of the most mature clinical data we’ve seen for a pan-mutant KRAS inhibitor, and the results look promising.
We saw early data for KRAS G12D-specific inhibitors in CRC at ESMO, but G12D represents only a subset of KRAS-mutant CRC. Broader mutant coverage could be exciting here.
ERAS-0015: This pan-RAS molecular glue demonstrated a 44% ORR, with encouraging activity across KRAS mutant alleles. Small cohorts, but an impressive early signal and potential best-in-class profile.
PAQ PT0253: A KRAS G12D degrader showed early evidence of activity in patients previously treated with KRAS-targeted therapies. Numbers are tiny, but an intriguing signal that a different mechanism of action – protein degradation – may overcome some mechanisms of resistance to KRAS inhibition.
Exciting progress across different approaches to targeting RAS, and a privilege to help bring some of these therapies to patients at Sarah Cannon Research Institute”
You may also be interested in:
Updated RMC-GI-102 Trial Results to Be Presented at ENA 2026 – Revolution Medicines
Sarah Cannon Research Institute Presents More Than 85 Abstracts and Presentations at ESMO 2026
The European Commission Approves Revolution Medicines’ Daraxonrasib for Metastatic Pancreatic Cancer
